Predicting the public health impact of antiretrovirals: preventing HIV in developing countries
The recent U.S. government $15 billion pledged for AIDS in Africa and the Caribbean has opened a debate regarding what proportion of this sum should be allocated to prevention versus treatment. Researchers from UCLA and Harvard Medical School argue, with caution, that antiretrovirals should be considered as a prevention tool and not simply as a therapeutic tool.
By Sally M. Blower and Paul Farmer
[About AIDScience articles] [See recent AIDScience articles]
Monocyte protein profiles may predict HIV-1–associated dementia (HAD)
Certain protein patterns in blood cells may be a sign an HIV-infected patient is at risk of dementia. The study supports the hypothesis that changes in monocyte function parallel the development of HAD. Neurology 60, 1931 (2003).
How many HIV preventive vaccine trials are underway?
The International AIDS Vaccine Initiative (IAVI) has introduced a new feature, "Clinical Trials Watch," which will track ongoing clinical testing of HIV vaccines. Download a PDF of the document with details on types of vaccines, sponsors/manufacturers, sites, etc., updated 16 June 2003.
HIV testing United States, 2001
To characterize the prevalence of HIV-antibody testing among U.S. adults, CDC analyzed data from the 2001 Behavioral Risk Factor Surveillance System (BRFSS). The findings document variability in HIV testing prevalence by area and by sex within areas, underscoring the ongoing need to promote voluntary HIV counseling and testing. MMWR 52(23), 540, 13 June, 2003.